severe osteoporosis
Endocrinology · 2018–2024
3decisions
1medicine
3carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| romosozumab Treatment of severe osteoporosis in the first-line setting in patients at very high risk of fracture defined as those with a BMD T-score of ≤-2.5 and either a… | Mar 2024 | Recommended with restriction | input received Healthy Bones Australia |
| romosozumab Treatment of severe established osteoporosis in patients at very high risk of fracture, defined by specific BMD T-score and fracture history criteria, for… | Mar 2023 | Recommended with restriction | 1 individuals Healthy Bones Australia · Bones Australia · Musculoskeletal Australia · CreakyJoints Australia |
| romosozumab Treatment of severe osteoporosis in patients with multiple minimal trauma fractures, at least one symptomatic fracture, and bone mineral density T-score ≤ -3.0. | Nov 2018 | Not recommended | input received |
Who spoke
Healthy Bones Australia · Bones Australia · Musculoskeletal Australia · CreakyJoints Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.